<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01961531</url>
  </required_header>
  <id_info>
    <org_study_id>291</org_study_id>
    <nct_id>NCT01961531</nct_id>
  </id_info>
  <brief_title>BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)</brief_title>
  <official_title>BrUOG 291: FIVE FRACTION PARTIAL BREAST IRRADIATION USING NON-INVASIVE IMAGE-GUIDED BREAST BRACHYTHERAPY (NIBB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Watson cancer center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Treatment Centers of America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety of 5 fraction accelerated partial brest irradiation in more convenient 5&#xD;
      fraction schedule.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the rate of early and intermediate toxicity related&#xD;
      to accelerated partial breast irradiation (APBI) delivered in a more convenient 5 fraction&#xD;
      schedule using non-invasive image-guided breast brachytherapy (NIBB) (AccuBoost System) in&#xD;
      women with resected, early stage breast cancer.&#xD;
&#xD;
      Non-invasive image-guided breast brachytherapy (NIBB), using advanced image-guided radiation&#xD;
      technology, has the potential to eliminate the disadvantages of the conventional APBI&#xD;
      techniques. NIBB facilitates non-invasive partial breast irradiation without the use of&#xD;
      catheters or implants. Yet by using breast immobilization and precise image-guidance, it&#xD;
      reduces non-target breast tissue within the irradiated field compared with other non-invasive&#xD;
      APBI techniques such as 3D-CRT. This has made NIBB an attractive approach to deliver APBI.&#xD;
&#xD;
      We hypothesize that NIBB delivered in 5 treatments will be a more convenient, safe and&#xD;
      effective modality to deliver partial breast irradiation.&#xD;
&#xD;
      Anticipated advantages of NIBB protocol treatment include:&#xD;
&#xD;
        -  Convenient treatment schedule&#xD;
&#xD;
        -  Short course can allow for increased patient access to treatment&#xD;
&#xD;
        -  Non-invasive approach&#xD;
&#xD;
        -  Increased accuracy with precise targeting of lumpectomy cavity using advanced imaging&#xD;
&#xD;
        -  Reduced irradiation of non-target breast tissue&#xD;
&#xD;
        -  Reduced skin toxicity&#xD;
&#xD;
        -  No heart or lung radiation exposure&#xD;
&#xD;
        -  Reduced late skin or breast toxicity&#xD;
&#xD;
        -  High rate of good or excellent cosmetic outcome&#xD;
&#xD;
        -  High rate of ipsilateral breast tumor control comparable to other APBI techniques&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">October 26, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Any Toxicity Related to the Radiation Treatment</measure>
    <time_frame>during treatment, 2 and 6 weeks post treatment and then every 6 months for up to 2 years</time_frame>
    <description>Any toxicity related to the radiation treatment will be scored and graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ipsilateral Breast Local Recurrence</measure>
    <time_frame>annually for 2 years post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Accuboost APBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28Gy delivered in 5 daily fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Accuboost APBI</intervention_name>
    <description>28Gy delivered in 5 daily fractions</description>
    <arm_group_label>Accuboost APBI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A confirmed histological diagnosis of invasive breast carcinoma or DCIS;&#xD;
&#xD;
          2. Age greater or equal to 50 years old;&#xD;
&#xD;
          3. Life expectancy &gt; 6 months;&#xD;
&#xD;
          4. Treated by breast conserving surgery&#xD;
&#xD;
          5. Pathologic lymph node negative, which includes (pN0 i-, i+);&#xD;
&#xD;
             Patients, who are at very low risk for sentinel node involvement and sentinel node&#xD;
             biopsy is not performed, are eligible if the treating investigator documents&#xD;
             clinically lymph node negative (cN0). These patients include:&#xD;
&#xD;
               -  DCIS&#xD;
&#xD;
               -  Microinvasion only&#xD;
&#xD;
               -  Pure tubular or mucinous histology&#xD;
&#xD;
               -  Patients â‰¥ 70yo with T1a-T1c; estrogen receptor +&#xD;
&#xD;
          6. Pathologic tumor size&#xD;
&#xD;
               1. less than or equal to 2 cm for invasive disease;&#xD;
&#xD;
               2. less than or equal to 3 cm for DCIS;&#xD;
&#xD;
          7. Estrogen receptor positive if invasive disease (DCIS can be ER negative)&#xD;
&#xD;
          8. Negative surgical margins greater than or equal to 2 mm. A margin of &lt;2mm is&#xD;
             acceptable if at natural boundary, i.e. skin or pectoralis fascia.&#xD;
&#xD;
          9. No lymphovascular invasion;&#xD;
&#xD;
         10. ECOG performance status of 0-2 (Appendix 1);&#xD;
&#xD;
         11. Informed consent signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known BRCA 1/2 Mutation; (BRCA 1 and 2 testing is not required)&#xD;
&#xD;
          2. Active lupus or scleraderma;&#xD;
&#xD;
          3. Pregnancy;&#xD;
&#xD;
          4. Psychiatric or addictive disorder that would preclude attending follow-up;&#xD;
&#xD;
          5. Neoadjuvant chemotherapy (adjuvant chemotherapy is permitted);&#xD;
&#xD;
          6. Suspicious remaining microcalcification on post-surgery mammogram (unless biopsy&#xD;
             proven benign);&#xD;
&#xD;
          7. pN+ on axillary dissection or in the sentinel lymph node biopsy (N0i+ are considered&#xD;
             node negative and are not excluded);&#xD;
&#xD;
          8. Multicentric disease;&#xD;
&#xD;
          9. Paget's disease of the nipple;&#xD;
&#xD;
         10. Breast Implants&#xD;
&#xD;
         11. Distant metastases;&#xD;
&#xD;
         12. Lumpectomy cavity not well visualized on AccuBoost imaging;&#xD;
&#xD;
         13. Lumpectomy cavity with 1cm margin (CTV/PTV) not adequately encompassed by any&#xD;
             available applicator.&#xD;
&#xD;
         14. Breast separation with compression &gt; 8cm at time of simulation.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaroslaw Hepel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Cancer Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 10, 2013</study_first_submitted>
  <study_first_submitted_qc>October 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2013</study_first_posted>
  <results_first_submitted>January 27, 2020</results_first_submitted>
  <results_first_submitted_qc>August 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 25, 2020</results_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>Jaroslaw Hepel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>DCIS</keyword>
  <keyword>IDC</keyword>
  <keyword>Invasive breast carcinoma</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Accuboost APBI</title>
          <description>28Gy delivered in 5 daily fractions&#xD;
Accuboost APBI: 28Gy delivered in 5 daily fractions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Accuboost APBI</title>
          <description>28Gy delivered in 5 daily fractions&#xD;
Accuboost APBI: 28Gy delivered in 5 daily fractions</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.45" lower_limit="50" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Any Toxicity Related to the Radiation Treatment</title>
        <description>Any toxicity related to the radiation treatment will be scored and graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0.</description>
        <time_frame>during treatment, 2 and 6 weeks post treatment and then every 6 months for up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Accuboost APBI</title>
            <description>28Gy delivered in 5 daily fractions&#xD;
Accuboost APBI: 28Gy delivered in 5 daily fractions</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Any Toxicity Related to the Radiation Treatment</title>
          <description>Any toxicity related to the radiation treatment will be scored and graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ipsilateral Breast Local Recurrence</title>
        <time_frame>annually for 2 years post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Accuboost APBI</title>
            <description>28Gy delivered in 5 daily fractions&#xD;
Accuboost APBI: 28Gy delivered in 5 daily fractions</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ipsilateral Breast Local Recurrence</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data was collected from signing of ICF until 5 years post treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Accuboost APBI</title>
          <description>28Gy delivered in 5 daily fractions&#xD;
Accuboost APBI: 28Gy delivered in 5 daily fractions</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Shoulder Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Contralateral Breast Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fibrosis-cosmesis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Soreness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Breast Volume/Hypoplasia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Breast Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Breast Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Skin Reaction</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Skin Induration/Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Telangiectasia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Skin Atrophy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypopigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jaroslaw Hepel, MD</name_or_title>
      <organization>BrUOG- Brown University Oncology Research Group</organization>
      <phone>401-863-3000</phone>
      <email>BrUOG@brown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

